Aurobindo Pharma to acquire Natrol for $132.5 Mn

Aurobindo Pharma USA (subsidiary of Aurobindo Pharma Limited) emerged as the highest bidder for acquisition of nutritional supplement maker, Natrol Inc, and other affiliate entities

mergersandacquisitions-9464665-smaller

(Photo Courtesy: www.healthcare-informatics.com)

The bid is valued at US$132.5 million.

Natrol manufactures and sells nutritional supplements in the US and other international market.

This acquisition is subject to final approval by the US Court and other statutory approvals as may be required, including any termination of the waiting period or approval under the HSR Act, and closing conditions as per the Asset Purchase Agreement.

Barclays acted as the sole financial advisor, and Sullivan & Cromwell LLP acted as the legal counsel to Aurobindo USA.

This announcement does not constitute a recommendation to the shareholders or potential investors.

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X